Abstracts Archive - Page 2311 of 2425 - ACR Meeting Abstracts

Abstract Number: 1666 • 2012 ACR/ARHP Annual Meeting
Short Term Use of Glucocorticoids Is Not Associated with Acute Risk of Myocardial Infarction
Steven C. Vlad¹, David T. Felson², Donald R. Miller³ and Yuqing Zhang⁴, ¹Clinical Epidemiology, Boston University, Boston, MA, ²Boston University, Boston, MA, ³Center for Health Quality, Outcomes, and Economic Research, Edith Nourse Rogers Memorial VA Hospital, Bedford, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Observational studies of both chronic and short term glucocorticoid (GC) use have suggested an elevated risk of acute myocardial infarction (MI). However this could…
Abstract Number: 1667 • 2012 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis On Recognition of Hypertension in a Medically Homed Population
Christie M. Bartels¹, Heather Johnson², Katya Voelker³, Patrick Mc Bride⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁴Cardiology/Medicine, Univ of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Impact of Rheumatoid Arthritis on Recognition of Hypertension in a Medically Homed PopulationBackground/Purpose: Numerous studies report increased cardiovascular disease (CVD) events and others describe increased…
Abstract Number: 1668 • 2012 ACR/ARHP Annual Meeting
Improving the Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis with a New Predictive Model Using the 10-Year Prospective Carre-Study
Alper M. van Sijl¹, Inge A.M. van den Oever¹, Mike J.L. Peters², Vokko P. van Halm³, Alexandre E. Voskuyl⁴, Yvo M. Smulders⁵ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ³Cardiology, Academic Medical Centre, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. Traditional CV risk factors do not…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 1670 • 2012 ACR/ARHP Annual Meeting
Microarray Analysis for miRNA Expression in Juvenile Dermatomyositis (JDM)
Dong Xu¹, Akadia Kachaochana², Gabrielle A. Morgan³, Elio F. Vanin⁴, Marcelo Bento Soares⁴ and Lauren M. Pachman¹, ¹Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ⁴Cancer Biology & Epigenomics Program, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: JDM, the most common of the idiopathic inflammatory myopathies, is a systemic vasculopathy, associated with premature development of cardiovascular disease. Studies by others had…
Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting
Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Kyle P. Chiang¹, Varun Gauba¹, Darin Lee¹, Minh-Ha T. Do¹, Jie J. Zhou², Feng Wang², Ying Buechler¹, Leslie Nangle¹, Zhiwen Xu², John Mendlein¹, Melissa Ashlock¹ and Jeffrey M. Greve¹, ¹aTyr Pharma, San Diego, CA, ²Scripps Laboratory, Institute for Advanced Study, Hong Kong University of Science and Technology, Kowloon, Hong Kong
Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…
Abstract Number: 1672 • 2012 ACR/ARHP Annual Meeting
Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis
Nicholas Young¹, Rahul Sharma², Alexandra Friedman³, Benjamin Kaffenberger¹ and Wael N. Jarjour⁴, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Medicine, University of Virginia Health System, Charlottesville, VA, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Myositis is associated with an inflammatory process that results in pronounced muscle weakness and is observed in some regulatory T cell (Treg) deficient mouse…
Abstract Number: 1673 • 2012 ACR/ARHP Annual Meeting
Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies
Zoe Betteridge¹, Sarah Tansley¹, Harsha Gunawardena², Lucy R. Wedderburn³, Hector Chinoy⁴, Robert G. Cooper⁵, Jiri Vencovsky⁶, Lenka Plestilova⁷, Ingrid E. Lundberg⁸, Katalin Danko⁹, Melinda Vincze¹⁰, Neil McHugh¹¹, UK JDRG¹² and EuMyoNet¹³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom, ³Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁴Rheumatic Diseases Centre, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatic Diseaes Center, Salford Royal Foundation Trust, Salford, United Kingdom, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague 2, Czech Republic, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹University of Debrecen, University of Debrecen, Debrecan, Hungary, ¹⁰University of Debrecen, University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Institute of Child Health, London, United Kingdom, ¹³Rheumatology Unit, Stockholm, Sweden
Background/Purpose: Autoantibodies to MDA5 have been previously reported in Japanese patients with dermatomyositis (DM) and are associated with clinically-amyopathic DM and rapidly progressing interstitial lung…
Abstract Number: 1674 • 2012 ACR/ARHP Annual Meeting
Myeloid Related Proteins Induce Muscle Derived Inflammatory Mediators in Juvenile Dermatomyositis
Kiran Nistala¹, Hemlata Varsani², Helmut Wittkowski³, Thomas Vogl⁴, Petra Krol⁵, Vanita Shah², Kamel Mamchaoui⁶, Paul Brogan², Johannes Roth⁷ and Lucy R. Wedderburn², ¹Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ²Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ³Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Prague, Czech Republic, ⁶Institut de Myologie, Paris, France, ⁷Immunology, Institute of Immunology University of Muenster, Muenster, Germany
Background/Purpose: The etiopathogenesis of Juvenile Dermatomyositis (JDM) remains poorly understood. In particular the contribution of monocytes or macrophages, which are frequently observed to be an…
Abstract Number: 1675 • 2012 ACR/ARHP Annual Meeting
Myositis Autoimmunity and Muscle Weakness Are Linked to TNF-Alpha Suppression of Micrornas-1, 133, and 206 in Myoblasts and Myocytes
Robert Georgantas III¹, Katie Streicher¹, Steven A. Greenberg², Lydia Greenlees³, Wei Zhu³, Philip Brohawn⁴, Brandon W. Higgs⁴, Megan Czapiga⁵, Chris Morehouse⁴, Laura Richman⁶, Bahija Jallal⁴, Koustubh Ranade⁵ and Yihong Yao⁶, ¹Translational Science, Medimmune, Inc, Gaithersburg, MD, ²Department of Neurology, Brigham Women's Hospital, Harvard Medical School, Boston, MA, ³Translational Science, MedImmune, LLC, Gaithersburg, MD, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁵Translational Science, MedImmune, Inc, Gaithersburg, MD, ⁶Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose: The molecular basis of myopathies such as dermatomyositis, polymyositis and inclusion-body myositis, which are characterized by chronic muscle inflammation followed by long term skeletal…
Abstract Number: 1676 • 2012 ACR/ARHP Annual Meeting
Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter Study
Carolina Birolo¹, Maria Elisabetta Zannin², Svetlana Arsenyeva³, Rolando Cimaz⁴, Elisabetta Miserocchi⁵, Margarita Dubko⁶, Chantal Deslandre⁷, Fernanda Falcini⁸, Maria Alessio⁹, Francesco La Torre¹⁰, Ekaterina Denisova¹¹, Irina Nikishina¹² and Francesco Zulian¹³, ¹Department of Pediatrics, Rheumatology Unit, University of Padua, Padua, Italy, ²Department of Pediatrics, Ophthalmology Unit, University of Padua, Padua, Italy, ³Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Russia, ⁴Rheumatology Unit, A. Meyer Children's Hospital, Florence, Italy, ⁵Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, ⁶State Pediatric Medical University, Saint-Petersburg, Russia, ⁷Rheumatology, Cochin Hospital, Paris, France, ⁸Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ⁹Department of Pediatrics, Rheumatology Unit, University of Naples Federico II, Naples, Italy, ¹⁰DIMIMP-University, Rheumatologic Section, Bari, Italy, ¹¹Helmgoltz Moscow Recearch Institute of Eye Diseases, Moskow, Russia, ¹²Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ¹³Department of Pediatrics, University of Padua, Padova, Italy
Background/Purpose: Anterior uveitis is a serious complication of Juvenile Idiopathic Arthritis (JIA). Recently, Abatacept (ABA) has been used in children with JIA-uveitis who had failed…
Abstract Number: 1637 • 2012 ACR/ARHP Annual Meeting
A Novel Peptide Inhibiting the Binding Between C1q and Immunoglobulin Ameliorates Joint Destruction in Rats with Collagen-Induced Arthritis
Yu Moriguichi and Tetsuya Tomita, Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: C1q is the major subcomponent of the first component of complement protein. The activation of the complement is triggered by binding of C1q to…
Abstract Number: 1638 • 2012 ACR/ARHP Annual Meeting
Synovial Fibroblast Migration Is Modulated by the Focal Contact Protein Lasp-1
Adelheid Korb-Pap¹, Jan Hillen¹, Marianne Heitzmann¹, Catherine S. Chew², Stefan Butz³, Dietmar Vestweber⁴, Hermann Pavenstädt⁵ and Thomas Pap¹, ¹Institute of Experimental Muskuloskeletal Medicine, University Hospital Muenster, Muenster, Germany, ²Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA, ³Max Planck Institute of Molecular Biomedicine, Max Planck Institute of Molecular Biomedicine, Muenster, Germany, ⁴Max Planck Institute of Molecular Biomedicine, Muenster, Germany, ⁵Internal Medicine D, Department of Nephrology and Rheumatology, University Hospital Muenster, Muenster, Germany
Background/Purpose: RA synovial fibroblasts (SF) have been suggested to contribute to the spreading of disease through their ability to leave cartilage destruction sites, migrate via…
Abstract Number: 1639 • 2012 ACR/ARHP Annual Meeting
FLIP in Macrophages Promotes the Progression of Serum Transfer-Induced Arthritis
Qi Quan Huang¹, Robert Birkett², Renee E. Koessler¹, G. Kenneth Haines III³, Harris R. Perlman⁴ and Richard M. Pope⁵, ¹Medicine/Rheumatology, Northwestern University, Chicago, IL, ²Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Pathology, Yale University, New Haven, CT, ⁴Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁵Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose: Flip is well known as an anti-apoptotic protein induced by chronic inflammation that protects against death receptor-mediated apoptosis. Employing a FLIP myeloid lineage knock-out…
Abstract Number: 1640 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Mark C. Genovese¹, Anthony Sebba², Andrea Rubbert-Roth³, Juan José Scali⁴, Rieke Alten⁵, Joel M. Kremer⁶, Laura Pitts⁷, Emma Vernon⁷ and Ronald F. van Vollenhoven⁸, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²University of South Florida, Tampa, FL, ³University of Cologne, Cologne, Germany, ⁴Durand University Hospital, Buenos Aires, Argentina, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Roche, Welwyn Garden City, United Kingdom, ⁸Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tocilizumab (TCZ)—an IL-6 receptor inhibitor—has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving physical function in rheumatoid arthritis (RA) patients (pts). This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].